HK1109563A1 - Protein hydrolysate with antidiabetic effect - Google Patents
Protein hydrolysate with antidiabetic effectInfo
- Publication number
- HK1109563A1 HK1109563A1 HK08100116.1A HK08100116A HK1109563A1 HK 1109563 A1 HK1109563 A1 HK 1109563A1 HK 08100116 A HK08100116 A HK 08100116A HK 1109563 A1 HK1109563 A1 HK 1109563A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- blood sugar
- protein hydrolysate
- antidiabetic effect
- hyperglycemia
- lowering
- Prior art date
Links
- 108010009736 Protein Hydrolysates Proteins 0.000 title 1
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003531 protein hydrolysate Substances 0.000 title 1
- 239000008280 blood Substances 0.000 abstract 3
- 210000004369 blood Anatomy 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 208000002249 Diabetes Complications Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000001421 hyperglycemia Diseases 0.000 abstract 2
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229940125708 antidiabetic agent Drugs 0.000 abstract 1
- 230000003345 hyperglycaemic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62784304P | 2004-11-15 | 2004-11-15 | |
| PCT/JP2005/021318 WO2006052031A1 (en) | 2004-11-15 | 2005-11-15 | Protein hydrolysate with antidiabetic effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1109563A1 true HK1109563A1 (en) | 2008-06-13 |
Family
ID=36336683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK08100116.1A HK1109563A1 (en) | 2004-11-15 | 2008-01-07 | Protein hydrolysate with antidiabetic effect |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090155376A1 (xx) |
| EP (1) | EP1824501B1 (xx) |
| JP (1) | JP4808218B2 (xx) |
| KR (1) | KR101219146B1 (xx) |
| CN (1) | CN101060854B (xx) |
| AT (1) | ATE439854T1 (xx) |
| AU (1) | AU2005302921B2 (xx) |
| CA (1) | CA2585442A1 (xx) |
| DE (1) | DE602005016144D1 (xx) |
| DK (1) | DK1824501T3 (xx) |
| ES (1) | ES2328835T3 (xx) |
| HK (1) | HK1109563A1 (xx) |
| WO (1) | WO2006052031A1 (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5041780B2 (ja) * | 2006-10-23 | 2012-10-03 | エムジーファーマ株式会社 | 肝障害改善組成物 |
| AU2008284709C1 (en) * | 2007-08-07 | 2014-06-05 | Mg Pharma Inc. | Anti-hypertensive agent |
| JP4864064B2 (ja) * | 2008-10-30 | 2012-01-25 | エムジーファーマ株式会社 | 抗糖尿病作用を有するペプチドおよびその用途 |
| WO2018001273A1 (zh) * | 2016-06-30 | 2018-01-04 | 江西本草天工科技有限责任公司 | 肽或其盐、其制备方法、及其制备预防和/或治疗肝损伤药物的用途 |
| CN107551258B (zh) * | 2016-06-30 | 2021-01-05 | 江西本草天工科技有限责任公司 | 用于预防和/或治疗肝损伤的vvyp |
| CN111937811A (zh) * | 2020-08-19 | 2020-11-17 | 河源兴泰农牧股份有限公司 | 一种猪的生态健康养殖方法 |
| JP2024102740A (ja) * | 2023-01-19 | 2024-07-31 | ロート製薬株式会社 | 疲労軽減又は疲労回復促進用組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452888A (en) * | 1980-07-10 | 1984-06-05 | Terumo Corporation | Process for producing a low-molecular weight peptide composition and nutrient agent containing the same |
| US4885486A (en) * | 1987-12-21 | 1989-12-05 | Sundstrand Corp. | Darlington amplifier with high speed turnoff |
| US5723443A (en) * | 1988-02-02 | 1998-03-03 | Hankyu-Kyoei Bussan Co. Ltd. | Lipid metabolism promoting agent and its use |
| CA1335567C (en) * | 1988-02-02 | 1995-05-16 | Kyoichi Kagawa | Lipid metabolism promoting agent |
| JP2764276B2 (ja) * | 1988-09-06 | 1998-06-11 | 仙味エキス株式会社 | 機能性新規ペプチド及びその利用 |
| JP3137273B2 (ja) * | 1992-06-16 | 2001-02-19 | 明治乳業株式会社 | 糖尿病に有効な組成物 |
| JP3312944B2 (ja) * | 1993-03-24 | 2002-08-12 | 伊藤ハム株式会社 | 脂肪細胞分化抑制ペプチド及び当該ペプチドを有効成分とする脂肪細胞分化抑制剤 |
| JP2805194B2 (ja) * | 1996-03-22 | 1998-09-30 | 阪急共栄物産株式会社 | 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤 |
-
2005
- 2005-11-15 EP EP05804084A patent/EP1824501B1/en not_active Not-in-force
- 2005-11-15 CN CN2005800390938A patent/CN101060854B/zh active Active
- 2005-11-15 WO PCT/JP2005/021318 patent/WO2006052031A1/en active Application Filing
- 2005-11-15 US US11/719,287 patent/US20090155376A1/en not_active Abandoned
- 2005-11-15 CA CA002585442A patent/CA2585442A1/en not_active Abandoned
- 2005-11-15 KR KR1020077013379A patent/KR101219146B1/ko active IP Right Grant
- 2005-11-15 AU AU2005302921A patent/AU2005302921B2/en not_active Ceased
- 2005-11-15 JP JP2007522327A patent/JP4808218B2/ja active Active
- 2005-11-15 AT AT05804084T patent/ATE439854T1/de active
- 2005-11-15 DK DK05804084T patent/DK1824501T3/da active
- 2005-11-15 ES ES05804084T patent/ES2328835T3/es active Active
- 2005-11-15 DE DE602005016144T patent/DE602005016144D1/de active Active
-
2008
- 2008-01-07 HK HK08100116.1A patent/HK1109563A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1824501B1 (en) | 2009-08-19 |
| KR101219146B1 (ko) | 2013-01-07 |
| CA2585442A1 (en) | 2006-05-18 |
| WO2006052031A1 (en) | 2006-05-18 |
| EP1824501A4 (en) | 2008-04-09 |
| DK1824501T3 (da) | 2009-12-21 |
| US20090155376A1 (en) | 2009-06-18 |
| KR20070086160A (ko) | 2007-08-27 |
| JP4808218B2 (ja) | 2011-11-02 |
| ES2328835T3 (es) | 2009-11-18 |
| AU2005302921A1 (en) | 2006-05-18 |
| ATE439854T1 (de) | 2009-09-15 |
| EP1824501A1 (en) | 2007-08-29 |
| CN101060854B (zh) | 2012-02-08 |
| DE602005016144D1 (de) | 2009-10-01 |
| JP2008519758A (ja) | 2008-06-12 |
| AU2005302921B2 (en) | 2010-09-23 |
| CN101060854A (zh) | 2007-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1109563A1 (en) | Protein hydrolysate with antidiabetic effect | |
| PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| EA201101187A1 (ru) | Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами | |
| WO2006044531A3 (en) | Antisense modulation of ptp1b expression | |
| WO2010029089A3 (en) | Combination therapy for the treatment of diabetes and related conditions | |
| DK1181043T3 (da) | Anvendelse af exendiner og agonister dertil til behandling af svangerskabsdiabetes mellitus | |
| WO2005113016A3 (en) | Modulation of glucose-6-phosphatase translocase expression | |
| BRPI0606727A (pt) | terapia de combinação para o tratamento de diabetes e condições relacionadas com ele e para o tratamento de condições melhoradas através de aumento no nìvel de glp-1 no sangue | |
| EA201101191A1 (ru) | Фармацевтическая композиция, включающая ингибитор sglt-2, ингибитор дпп-iv и необязательно другой антидиабетический агент, и ее применение | |
| AU2010212865A8 (en) | SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia | |
| EA200870575A1 (ru) | Композиции и способы лечения застойной сердечной недостаточности | |
| GEP20135724B (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes | |
| MX2008002370A (es) | Exendina para tratar la diabetes y reducir el peso del cuerpo. | |
| WO2006044556A3 (en) | Dual inhibitors of lipoxygenase for treating diabetes | |
| WO2007002836A3 (en) | Methods and compositions for the prevention and treatment of kidney disease | |
| EA200900940A1 (ru) | Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное | |
| WO2007041365A3 (en) | 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes | |
| WO2008055940A3 (en) | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions | |
| BRPI0511703B8 (pt) | composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição | |
| WO2008108957A3 (en) | Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain | |
| WO2008043087A3 (en) | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors | |
| WO2008155900A1 (ja) | 糖鎖付加glp-1ペプチド | |
| BRPI0606191A2 (pt) | compostos de amino e carboxamido tetracìclicos e métodos do seu uso | |
| GB2462947A (en) | Fatty Acid Oxidation Inhibitors Treating Hyperglycemia and Related Disorders. | |
| Sarkar et al. | Effects of resveratrol and mangiferin on PPARγ and FALDH gene expressions in adipose tissue of streptozotocin-nicotinamide-induced diabetes in rats |